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INTRODUCTION
Augmentation and reconstruction mammaplasty are 
among the most frequently performed cosmetic proce-
dures and one of the relatively common complications is 
capsular contracture (CC) (Del Pozo et al., 2009). CC in-
volves tightening of the collagen capsule that forms around 
the breast implant, which can be painful and very often 
distorts the breast (Galdiero et al., 2018).  CC remains the 
most common cause of breast surgery revision. Various 
studies have indicated CC incidences ranging from 5% to 
74% of breast reconstructive surgeries and approximately 
45,000 patients with CC are diagnosed annually (Asplund 
et al., 1996; Wong et al., 2006; Handel et al., 2006; Cun-
ningham and McCue, 2009). CC is classified according to 
the Baker classification system (Little and Baker, 1980) as 
follows: grade I, breast absolutely natural; grade II, min-
imum contracture; grade III, moderate contracture; and 
grade IV, severe contracture. Possible causes of contrac-
ture could be chemical composition and surface texture of 
the implant and the presence of bacterial biofilms (Rieger 
et al., 2013).  Bacteria that live on the skin and within the 
breast ducts can contaminate the surface of the breast im-
Corresponding author:
Maria Pia Conte
E-mail: mariapia.conte@uniroma1.it
©2018 by EDIMES - Edizioni Internazionali Srl. All rights reserved
plant at the time of insertion forming biofilm (Chessa et 
al., 2016). Microbial biofilms could represent a trigger for 
chronic peri-implant inflammation and multiple animal 
and clinical studies have shown a correlation between bio-
films and CC (Hu et al., 2015; Chessa et al., 2016). Biofilms 
are usually polymicrobial and display elevated resistance 
to antibiotics, disinfectants, and the immune response 
(Donlan and Costerton, 2002). Microbiological identifica-
tion of the bacteria involved in biofilm formation is es-
sential to develop preventive measures and to establish a 
correct treatment. In general, the microorganisms most 
commonly reported are Staphylococcus aureus, coagu-
lase-negative staphylococci (CoNS), particularly Staphylo-
coccus epidermidis, and Propionibacterium acnes (Pajkos 
et al., 2003; Netscher et al., 1995). 
This report describes a case of a patient with Baker grade 
II capsular contracture in which microbial agents from 
capsula and prosthesis were identified and characterized 
by their ability to form biofilms. Furthermore, ultras-
tructural analysis revealed biofilm directly on the breast 
implant, confirming results obtained by microbiological 
assay.
CASE REPORT
Breast implants and capsules removed from a 35-year-old 
patient (Figure 1) with Baker grade II capsular contracture 
were analyzed by microbiological procedures. The patient 
had undergone her first surgery two years before with an-
other surgeon. Clinical symptoms of capsular contracture 
had started six months after the first surgery with gradually 
increasing breast firmness and lateral implant dislocation. 
Key words:
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SUMMARY
Capsular contracture is one of the most common complications of implant-based breast augmentation. 
Despite its prevalence, the etiology of capsular contracture remains controversial although the surface tex-
ture of the breast implant, the anatomical position of the prosthesis and the presence of bacterial biofilm 
could be considered trigger factors. In fact, all medical implants are susceptible to bacterial colonization 
and biofilm formation. The present study demonstrated the presence of microbial biofilm constituted by 
cocci in a breast implant obtained from a patient with Baker grade II capsular contracture. This suggests 
that subclinical infection can be present and involved in low grade capsular contracture.
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During explantation, two specimens were taken (Figure 2). 
These included capsule biopsies and breast implants. For 
microbiological studies, each specimen was cut into small 
fragments, approximately 10-20 mm, transferred to a 6-ml 
of Brain Heart Infusion Broth (Oxoid, Rome, Italy) and 
incubated up to 72 hours at 37°C under vigorous shak-
ing. Positive cultures were plated on blood agar, Mannitol 
Salt Agar and Mac Conkey 3 agar (Oxoid, Rome, Italy), 
and incubated for 24 to 72 hours at 37°C. Bacterial colony 
identification and antibiotic susceptibility were done us-
ing the Vitek 2 system (bioMérieux) and molecular iden-
tification method. 16S rDNA gene sequencing was used 
to identify the isolated strains. Genomic DNA extraction 
was achieved by suspending three to five bacterial colo-
nies in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.8) and 
heating at 100°C for 20 min. Universal 16S rDNA bacterial 
primers (V1-V9) 8F (5’-AGAGTTTGATCCTGGCTCAG-3’) 
and 1492R (5’-GGTTACCTTGTTACGACTT-3’) were used 
to amplify the 16S rDNA using 10 ng of genomic DNA iso-
lated from each strain. PCR products were visualized on 
a 1% agarose gel. Amplicons were quantitated and bi-di-
rectional sequenced using primers 8F and 1492R (Bio-Fab 
Research labs). The 16S rDNA sequences were compared 
with those available in the GenBank using the BLAST pro-
gram (http://blast.ncbi.nlm.nih.gov/blast). S. epidermidis, 
S. hominis, and S. warnerii were identified. The antibi-
otic susceptibility analysis showed that among antibiotic 
tested (Cefoxitin screen, Penicillin, Oxacillin, Gentamicin, 
Levofloxacin, Clindamycin, Erythromycin, Linezolid, 
Daptomycin, Teicoplanin, Vancomycin, Tetracycline, Tige-
cycline, Fosfomycin, Fusidic acid, Mupirocin, Rifampin, 
Trimethoprim-sulfamethoxazole), S. epidermidis was re-
sistant to Erythromycin (MIC≥8 μg/ml) and Teicoplanin 
(MIC=16 μg/ml); S. warneri was resistant to Clindamycin 
(MIC≥4 μg/ml) and Daptomycin (MIC=4 μg/ml); S. homi-
nis was resistant to Erythromycin (MIC≥8 μg/ml), Clinda-
mycin (MIC=0.5 μg/ml) and Teicoplanin (MIC=8 μg/ml).
Biofilm formation was assayed as previously described 
(Stepanović et al., 2007). The S. epidermidis ATCC 35984 
strain was used as a positive control. Biofilms were quan-
tified by measuring the absorbance at λ 570 nm and the 
ratio 570/595 nm was calculated to normalize bacterial 
biofilm production to bacterial growth. The average of 
OD values was calculated and cutoff values (ODc) were 
established. ODc is defined as the average of OD of nega-
tive control + three standard deviations. According to their 
absorbance, isolates were defined as strong when (4xOD-
c<OD), medium (2xODc<OD≤ 4xODc), weak (ODc<OD≤ 
2xODc) or non-biofilm producers (OD≤ ODc). Results ob-
tained showed that all strains were strong biofilm produc-
ers being OD>4xODc: S. epidermidis (4.5±0.7), S. warneri 
(4.12±1.2) and S. hominis (4.73±1.1) and S. epidermidis 
ATCC 35984 a strong biofilm producer used as positive 
control (4.72±0.85).
The presence of biofilm on implant was revealed by Ul-
tra-high resolution Field Emission Gun Scanning Elec-
tron Microscopy (FEG-SEM, FEI Company). A fragment 
of the implant was fixed in 2.5% glutaraldehyde in 0.1 
M cacodylate buffer (pH 7.4) at 4°C for 24 h, and post-
fixed in 1% OsO4 solution.  Samples were then dehydrated 
through a graded series of ethanol solutions, dried with 
hexamethyldisilazane and gold sputtered. Secondary elec-
tron images were performed with an acceleration volt-
age of 20 KV. The images were processed for display us-
ing Photoshop (Adobe Systems Inc., San Jose, CA, USA) 
software. FEG-SEM analysis showed two morphological 
types of biofilm images (Figure 3). Coccoid cells, found 
by ultrastructural analysis, confirmed results obtained by 
microbiological assay. Bacterial cells appeared aggregated 
to form biofilm: coccoid cells were either saturated with 
extracellular material that obscured individual cells or ag-
gregated with many individual cells.
DISCUSSION
The etiology of CC is not completely understood. Capsule 
formation itself is known to be a normal response to all 
kind of foreign bodies, but contracture is not. CC forma-
tion is likely a multifactorial process and several putative 
factors have been proposed, such as a previous contrac-
Figure 1 - Preoperative view of a 35-year-old patient with 
Baker grade II capsular contracture. The patient had under-
gone her first surgery two years before with another surgeon.
Figure 2 - Implants and capsules removed.
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ture, and oncologic patients treated with radiotherapy 
(Galdiero et al., 2018). Other factors are placement of an 
incision site, hypertrophic scarring, overactive inflamma-
tory response, and foreign body reaction from powdered 
gloves, dust, or silicone gel leakage (Adams, 2009). Several 
lines of preliminary evidence suggest a role of microbial 
infection in CC pathogenesis (Virden et al., 1992; Dobke 
et al., 1995). Local skin flora, such as coagulase-negative 
staphylococci, Propionibacterium acnes, and Corynebac-
terium species (Byrd et al., 2018) is the most frequently 
involved in CC (Bartsich et al., 2011). The breast skin may 
harbor bacteria that remain present during surgery in ster-
ile conditions and may gain access to breast implants dur-
ing or following placement. Moreover, in specific breast 
regions like the nipples, contamination during surgery 
is more frequent for the highest concentration of local 
bacteria (Bartsich et al., 2011). A significant association 
between CC and the presence of skin bacteria on the ex-
planted breast implants has been also demonstrated (Del 
Pozo et al., 2009). Indeed, bacteria of the normal skin flo-
ra, such as S. epidermidis, have been found involved in the 
formation of biofilm on mammary implants (Chessa et al., 
2016).  Some have suggested that bacteria form biofilms 
on the implant, stimulating fibrosis around the implant 
and, ultimately, capsular contracture (Dobke et al., 1994; 
Netscher, 2004). Biofilms are microbial communities that 
are attached to a surface, including living tissue, implants 
and medical devices. These infections are difficult to treat, 
and as a result, they become persistent and chronic. Dif-
ferent literature data show a correlation between the pres-
ence of microbial biofilms on various medical implants 
and persistent inflammation of the surrounding tissue 
(Costerton et al., 2005; Arciola et al., 2012). It appears that 
microbial biofilms also form on breast implants and might 
contribute to a chronic inflammatory response and thus 
formation of capsular fibrosis and subsequent contracture 
(Schreml et al., 2007).  Investigations of biofilms on mam-
mary implants began by studying CC. Virden et al. (1992) 
were among the first to demonstrate a correlation between 
biofilms on silicone shells and the risk of CC. Several ad-
ditional studies have attempted to determine the patho-
physiology and prognosis of biofilm-related CC (Dobke et 
al., 1995; Pajkos et al., 2003) as well as potential prophy-
lactic and therapeutic measures. Studies conducted in an 
animal model have observed a correlation between bacte-
rial biofilm and CC. S. epidermidis was inoculated before 
implantation of a breast prosthesis and after two weeks 
biofilm was present both on the implant and on the cap-
sule (Ajdic et al., 2016).  Gualdiero et al. (2018) reported 
that patients with a clinical history of breast surgery or 
chronic inflammation are most susceptible to developing 
a CC caused by the formation of biofilm on the protheses. 
Based on the scientific evidence, we speculate that in our 
reported clinical case, biofilm formation could play a role 
in chronic inflammation and pathogenesis of CC in a pa-
tient with Baker grade II, although little evidence has been 
reported. Moreover, based on the types of isolates belong-
ing to skin flora such as S. epidermidis, S. warnerii and 
S. hominis, all strong biofilm producers, we could assess 
that endogenous flora could be a source of contamination 
(Bartsich et al., 2011). Interestingly, Arslan et al. (2011) re-
ported S. warnerii as a cause of endocarditis in a patient 
Figure 3 - Bacterial biofilm 
revealed by SEM. Thin biofilm 
matrix appeared due to bacte-
rial cells saturated with amor-
phous material (Figure 3A and 
B), which obscured individual 
cells and voluminous bacterial 
aggregates with many individ-
ual cells consistent with cocci 
(Figure 3C and D). Bacteria 
(thin arrows) and possible 
bacterial micro-colonies (thick 
arrows)
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who had a silicone mammoplasty. This leads us to specu-
late that S. warnerii chould be a potential pathogen caus-
ing subclinical infection during breast surgery in patients 
with the implant.
Preventive strategies to minimize implant contamination 
from endogenous breast flora appear to be the only pre-
ventive measures to reduce the risk of CC (Ajdic et al., 
2016). Therefore, prevention rather than treatment might 
be a better strategy.
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